Considering the promising results of the SURPASS and SURMOUNT trials, what additional factors or challenges must researchers address before adopting tirzepatide for conditions beyond Type 2 diabetes, such as non-alcoholic fatty liver disease (NAFLD)
However, it is important to recognize that ongoing use is typically required to maintain these benefits
Here's what my "transformation timeline" looked like: Week 1: For the first time in months, the aggressive shedding started to slow down
Its a long-term condition, and relapse is common if its not actively managed
Interest in medical weight management has surged as more people search online, asking whether GLP-1 patches work and whether these products truly support sustainable weight loss
Compare your progress to the expected weight loss trajectory for your dose level to determine if microdosing is producing adequate results